in the news

EndPoints News

Rare blood disorders biotech Hemab raises $135M, begins trek into clinic

Hemab Therapeutics, led by Alnylam vet Benny Sorensen and chaired by John Maraganore, has raised $135 million from a new crop of investors as it begins pushing its blood disorder programs into the clinic. Hemab’s Series B was led by Access Biotechnology, followed by Deep Track Capital, Avoro Capital, Invus, Rock Springs Capital and Danish

More

Endpoints News

PROTACs to RIPTACs: Arvinas founder snags $76M for next bet, Halda Therapeutics

A leader in the protein degradation space, Yale’s Craig Crews, is back with another biotech, Halda Therapeutics. On Tuesday, the startup announced $76 million in funding to take forward a new technology out of Crews’ lab, called RIPTACs, or Regulated Induced Proximity TArgeting Chimeras. The 26-employee startup emerged from hid decades-long work on heterobifunctional molecules,

More

Wall Street Journal

Biotech Startup Acelyrin Buys Drugmaker ValenzaBio in Stock Deal

Acelyrin said it acquired privately held ValenzaBio in an all-stock transaction but didn’t disclose further financial details of the acquisition. Acelyrin, which disclosed a $300 million venture financing in September led by Access Biotechnology, previously struck a deal with biotech Affibody AB to secure global rights to develop and commercialize a compound, izokibep, except in

More

Endpoints News

Verona says second PhIII for COPD drug hits the mark, plans 2023 NDA filing

UK-based biotech Verona Pharma said Tuesday morning that its drug, ensifentrine, passed its second late-stage trial for the common lung disease COPD. In August, Verona reported the drug succeeded in the first of its two Phase III trials. Now, Verona will package together the new trial data in its approval filing to the FDA, which

More